Welcome to our dedicated page for HeartSciences Warrant news (Ticker: HSCSW), a resource for investors and traders seeking the latest updates and insights on HeartSciences Warrant stock.
Heart Test Laboratories Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The company aims to enhance healthcare by making cardiac screening more valuable, especially in frontline clinical settings.
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) announced the results of the 2024 Annual Meeting of Shareholders, including the passing of important resolutions and an adjournment in respect of Proposal 7. Approximately 54.37% of the Company’s outstanding shares were represented at the meeting. The shareholders approved the re-election of director nominees, the issuance of shares of common stock, the Equity Incentive Plan, the independent registered public accounting firm, and amendments to the Company’s Certificate of Formation. Proposal 7, which aimed to lower the quorum for future meetings, was adjourned until February 15, 2024 due to insufficient votes. The reconvened Annual Meeting will be held virtually, and shareholders are encouraged to vote by February 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) reminds shareholders to vote ahead of its 2023 Annual Meeting of Stockholders on January 17, 2024. All shareholders on record as of November 20, 2023, are entitled to participate and vote. Shareholders are encouraged to read the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) reported financial results for Q2 fiscal 2024, highlighting transformative changes through agreements with the Icahn School of Medicine at Mount Sinai, FDA confirmation for a standard 510(k) submission pathway, and expanded international distribution channels. The company also raised $9.6 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) has received FDA confirmation to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm to a more standard 510(k) submission from the De Novo process. The company aims to deliver innovative AI-ECG diagnosis from millions of existing ECG devices worldwide and is on track for FDA submission in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Heart Test Laboratories, Inc. (Nasdaq: HSCS; HSCSW) announced the closing of license agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) to develop and commercialize electrocardiographic AI algorithms and assets. The licenses result in Icahn Mount Sinai becoming a shareholder in the company. HeartSciences aims to bring new AI-powered ECG capabilities to market, enabling the early detection of heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd to be used in its heart screening program for the Association of Garda Sergeants and Inspectors. Cardiact has placed an initial order for 2,400 patient tests and established a new referral pathway directly to cardiology. This announcement follows recent positive developments, including agreements with Icahn School of Medicine at Mount Sinai and the creation of a new FDA product classification for AI-ECG algorithms, positioning AI-ECG as a transformative tool for early heart disease detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
HeartSciences announces transformative agreements with Icahn Mount Sinai and files FDA Pre-Submission Request
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, has been issued new patents in Brazil and the UAE, bringing its total patent portfolio to 33 international patents and 9 US patents. CEO Andrew Simpson expects AI to drive significant growth in the ECG market to $25 billion per year by 2032. HeartSciences also recently signed agreements with Mount Sinai to expand its cardiovascular disease screening capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HeartSciences CEO to present at Maxim Group's Virtual Tech Conference Series: Emerging Growth in A.I.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
HeartSciences partners with Icahn Mount Sinai to commercialize AI algorithms for cardiovascular disease detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of HeartSciences Warrant (HSCSW)?
The current stock price of HeartSciences Warrant (HSCSW) is $0.04 as of December 18, 2024.
What is Heart Test Laboratories Inc known for?
Heart Test Laboratories Inc is known for its AI-powered medical technology that transforms ECGs/EKGs to enable earlier detection of heart disease.
What is the primary objective of Heart Test Laboratories Inc?
The primary objective of Heart Test Laboratories Inc is to improve healthcare by making cardiac screening a more valuable tool in frontline or point-of-care clinical settings.
What recent achievement has Heart Test Laboratories Inc had?
Heart Test Laboratories Inc demonstrated that its MyoVista AI-ECG model outperformed conventional screening standards for Stage B Heart Failure.
What is the focus of Heart Test Laboratories Inc's technology?
The focus of Heart Test Laboratories Inc's technology is on utilizing AI to enhance ECG/EKG screenings for the early detection of heart conditions.
What recent patent did Heart Test Laboratories Inc receive?
Heart Test Laboratories Inc was granted an Indian Patent for its MyoVista® Wavelet Technology, affirming its commitment to innovation in heart disease detection.
HeartSciences Inc. Warrant
Nasdaq:HSCSW
HSCSW Rankings
HSCSW Stock Data
950.00k
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
United States of America
SOUTHLAKE